Joint Meeting 2026
LLS & SOHO JOINT MEETING 2026
CONTROVERSIES IN
HEMATOLOGICAL MALIGNANCIES
CME
ACCREDITED
Welcome Note
We are pleased to welcome you to the LLSK & SOHO Joint Meeting 2026 – Controversies in Hematological Malignancies, to be held on Wednesday, April 1st, 2026, at the Auditorium – National Library of Kuwait, Kuwait City.
This joint scientific meeting, organized in collaboration between the Leukemia & Lymphoma Society (LLS) and the Society of Hematologic Oncology (SOHO), focuses on key controversies in the management of hematological malignancies.
Leading regional and international experts will discuss areas where clinical evidence, guidelines, and real-world practice may differ.
The program follows a debate-driven format and covers major disease areas including chronic leukemias, plasma cell dyscrasias, lymphoma, and acute leukemias.
Sessions will address important treatment decisions, emerging therapies, transplant considerations, and the care of elderly and high-risk patients.
We look forward to welcoming you to Kuwait for a valuable scientific exchange and an engaging educational experience.
Dr. Ahmad Alhuraiji
Chairperson
Agenda
Explore the full schedule of sessions, discussions, and expert talks.
Session 1: Chronic leukemia
09:00 - 09:20
FD vs Continuous therapy in high risk CLL? Yes or no?
Dr. Nitin Jain 
Dr. Mariam Alasfour 
09:20 - 09:40
2GTKi vs STAMPi in frontline CML treatment
Dr. Ahmad Alhuraiji
Dr. Eman Abo Dalla 
09:40 - 10:00
Should we cytoreduce pts with idiopathic erythrocytosis. Yes or no?
Dr. Ahmad Alabdulkarim
Prof. Salam AlKindi 
10:00 - 10:10
Q&A
10:10 - 10:30
Satellite symposia
TBA
10:30 - 11:00
Coffee Break
Session 2: Plasma Cell dyscasia
Moderator: Dr. Mohammad S. Ebraheem - Dr. Bilal Alnouri
11:00 - 11:20
Early Action or Restraint? Navigating Smoldering Myeloma
Dr. Meletios Dimopoulos 
Dr. Ramesh Pandita 
11:20 - 11:40
Fixed Duration vs MRD Adaptation: Rethinking Treatment Endpoints
Dr. Ashutosh wachelaker 
Dr. Mohammad S. Ebraheem
11:40 - 11:50
Q&A
11:50 - 12:10
BiTEs, CAR-T, and Sequencing Chaos: Making Sense of High-Risk MM
Dr. Meletios Dimopoulos
Dr. Ashutosh wachelaker
12:10 - 12:30
Choosing the Right Path in WM: BTKi or Chemoimmunotherapy?
Dr. Ibrahim Al Nabhani
Dr. Bilal Alnouri
12:30 - 12:40
Q&A
12:40 - 13:00
Satellite symposia
TBA
13:00 - 14:00
Lunch break
Session 3: Lymphoma
Moderator : Dr. Abdulaziz Hamadah - Dr. Samar Ousia
14:00 - 14:20
Satellite symposia
TBA
14:20 - 14:40
BrECADD or N-AVD in upfront HL. (BrECADD
Dr. Ali Bazarbachi
Dr. Abdulwahab Altoura
14:40 - 15:00
Pola R-CHP or DA-EPOCH-R in DHL
Dr. Samar Ousia
Dr. Khaleel Alfaresi
15:00 - 15:10
Q&A
Session 4: Acute leukemia
Moderator : Dr. Fatima Khadadah - Dr. Yahya Almahmeed
15:10 - 15:30
TBI based vs. Chemo only conditioning for Allo HSCT in AML
Dr. Ayman Saad 
Dr. Ali Bazarbachi
15:30 - 15:40
Coffee Break
15:40 - 16:00
Is there a role for IC AML treatment in 2026, Yes or No?
Dr. Mansour Alfayez
TBA
16:00 - 16:10
Q&A
16:10 - 16:30
Ph+ B ALL: Is transplant needed in CR1? Yes or No
TBA
Dr. Iman Abou Dalle
16:30 - 16:50
Should we drop chemotherapy for elderly with ALL?
Dr. Nitin Jain
Dr. Hind Salama
16:50 - 17:00
Q&A
17:00 - 17:10
Closing Remarks
Our Speakers
Meet the distinguished speakers joining us to share their expertise and insights at this event.
Dr. Nitin Jain
Dr. Mariam Alasfour
Dr. Ahmad Alhuraiji
Dr. Eman Abo Dalla
Dr. Ahmad Alabdulkarim
Prof. Salam AlKindi
Dr. Meletios Dimopoulos
Dr. Ramesh Pandita
Dr. Ashutosh wachelaker
Dr. Mohammad S. Ebraheem
Dr. Ibrahim Al Nabhani
Dr. Bilal Alnouri
Dr. Ali Bazarbachi
Dr. Abdulwahab Altoura
Dr. Samar Ousia
Dr. Khaleel Alfaresi
Dr. Ayman Saad
Dr. Mansour Alfayez
Dr. Iman Abou Dalle
Dr. Hind Salama
Scientific Committee
The Scientific Committee behind this event, ensuring academic quality, scientific rigor, and excellence in program development.
Agenda Timeline
Follow the session flow with our interactive agenda timeline.
Not started yet
Upcoming Session
FD vs Continuous therapy in high risk CLL? Yes or no?
Dr. Nitin Jain &Dr. Mariam Alasfour
&Dr. Mariam Alasfour The Society of Hematologic Oncology (SOHO)
SOHO-Kuwait is part of the worldwide Society of Hematologic Oncology. In 2026, SOHO-Kuwait is honored to present a satellite meeting that extends SOHO’s educational mission to additional regions around the world.
-
Global professional society dedicated to clinicians, research scientists, and healthcare professionals specializing in hematologic cancers and related disorders.
-
Non-profit organization established in 2012 to advance worldwide research, education, prevention, clinical studies, and patient care in hematologic malignancies.
-
Mission-driven impact to accelerate international research and education by promoting the exchange of scientific information—founded and guided by world-renowned experts.
-
Education & networking through SOHO programs, meetings, and initiatives—connecting a worldwide community focused exclusively on hematologic oncology.
-
FREE membership — SOHO members gain access to worldwide educational resources and opportunities at no cost.
Membership is FREE. Join SOHO free of charge:
Join SOHO
Join SOHO
Become a member of the Society of Hematologic Oncology (SOHO) by joining FREE of charge at soho.click/join. As a member, you can join your local country chapter to receive updates on meetings and events in your region. Membership also provides access to SOHO Annual Meeting presentations, educational materials, and other exclusive member resources.
Free Membership Requirement
All ancillary SOHO meetings are required to offer FREE membership to all attendees through the main SOHO
membership system:
Target Audience
This program is designed for healthcare professionals involved in the diagnosis and management of hematologic malignancies, including:
-
Consultant physicians in hematology, hematologic oncology, and medical oncology
-
Bone marrow and stem cell transplant specialists
-
Junior clinicians and fellows seeking advanced, debate-driven, case-based learning in hematologic malignancies
-
Medical residents with a strong interest in leukemia, lymphoma, and plasma cell disorders
-
Physicians and researchers involved in novel therapies, cellular therapy, and clinical trials
-
Specialized nursing staff and allied healthcare professionals involved in the care of patients with hematological malignancies
The program is structured to deliver high-level scientific updates, expert debate, and practical clinical insights,
making it suitable for participants at different stages of training and clinical experience, from trainees to senior consultants.
Registration
Registration Deadline: 12:30 PM – 01 APRIL 2026
Sponsored By
Coming Soon
Sponsorship opportunities for this scientific joint meeting are currently available. Organizations interested in supporting this event and engaging with a specialized medical audience are welcome to contact us for further details.
💬 Contact Us on WhatsAppFrequently Asked Questions
Registration Details
- Please ensure you use a valid private email address during registration.
- All registration information must be accurate and up to date.
- Multiple registrations under the same name or email are not allowed.
Attendance Regulations
- Onsite Attendance: Please present your confirmed ticket received via email to collect your conference badge at the registration desk.
CME Certificate & Regulations
- Ensure all personal details are correct during registration to receive CME credits.
- CME credits are granted upon verified attendance via QR check-in at the event.
- Certificates will be sent post-event to your registered email.
Payment Method & Refund Policy
- Accepted payments: KNET, Visa, Mastercard, Diners, and AMEX.
- Tickets are non-refundable once purchased.
Contact Us
WhatsApp us